在一项针对马匹的剂量递增疫苗接种试验中，BPV-1 L1 病毒样颗粒的安全性和免疫原性。
Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.
机构信息
Large Animal Surgery and Orthopaedics, Equine Clinic, University of Veterinary Medicine, Vienna, Austria.
出版信息
Equine Vet J. 2012 Jan;44(1):107-11. doi: 10.1111/j.2042-3306.2011.00390.x. Epub 2011 Sep 6.
REASONS FOR PERFORMING STUDY
Infection with bovine papillomaviruses types 1 and 2 (BPV-1, BPV-2) can lead to the development of therapy-resistant skin tumours termed sarcoids and possibly other skin diseases in equids. Although sarcoids seriously compromise the welfare of affected animals and cause considerable economic losses, no prophylactic vaccine is available to prevent this common disease. In several animal species and man, immunisation with papillomavirus-like particles (VLP) has been shown to protect efficiently from papillomaviral infection.
HYPOTHESIS
BPV-1 L1 VLPs may constitute a safe and highly immunogenic vaccine candidate for protection of horses against BPV-1/-2-induced disease.
METHODS
Three groups of 4 horses each received 50, 100 or 150 µg of BPV-1 L1 VLPs, respectively, on Days 0, 28 and 168. Three control horses received adjuvant only. Horses were monitored on a daily basis for one week after each immunisation and then in 2 week intervals. Sera were collected immediately before, 2 weeks after each vaccination and one and 2 years after the final boost and analysed by pseudovirion neutralisation assay.
RESULTS
None of the horses showed adverse reactions upon vaccination apart from mild and transient swelling in 2 individuals. Irrespective of the VLP dose, all VLP-immunised horses had developed a BPV-1-neutralising antibody titre of ≥ 1600 plaque forming units (pfu)/ml 2 weeks after the third vaccination. Eight of 10 trial horses still available for follow-up had neutralising antibody titres ≥ 1600 pfu/ml one year and ≥ 800 pfu/ml 2 years after the last immunisation.
CONCLUSION
Intramuscular BPV-1 L1 VLP vaccination in horses is safe and results in a long-lasting antibody response against BPV-1. Neutralisation titres were induced at levels that correlate with protection in experimental animals and man.
POTENTIAL RELEVANCE
BPV-1 L1 VLPs constitute a promising vaccine candidate for prevention of BPV-1/-2-induced disease in equids.
研究目的
牛乳头瘤病毒 1 型和 2 型（BPV-1、BPV-2）感染可导致马等动物发生治疗抵抗性皮肤肿瘤，称为肉瘤，也可能导致其他皮肤疾病。尽管肉瘤严重损害受感染动物的福利，并造成巨大的经济损失，但目前尚无预防这种常见疾病的疫苗。在多种动物物种和人类中，用类乳头瘤病毒样颗粒（VLP）免疫已被证明能有效地预防乳头瘤病毒感染。
假设
BPV-1 L1 VLP 可能是一种安全且具有高度免疫原性的疫苗候选物，可保护马免受 BPV-1/-2 诱导的疾病。
方法
三组各有 4 匹马，分别在第 0、28 和 168 天接受 50、100 或 150 µg 的 BPV-1 L1 VLP。3 匹对照马仅接受佐剂。在每次免疫后，马每天监测一周，然后每两周监测一次。在每次接种前、第二次接种后两周以及最后一次加强免疫后 1 年和 2 年采集血清，并用假病毒中和测定法进行分析。
结果
除 2 例个体出现轻度和短暂肿胀外，所有马在接种后均未出现不良反应。无论 VLP 剂量如何，所有 VLP 免疫马在第三次接种后 2 周均产生了≥1600 蚀斑形成单位（pfu）/ml 的 BPV-1 中和抗体滴度。10 匹试验马中有 8 匹在最后一次免疫后 1 年仍具有≥1600 pfu/ml 的中和抗体滴度，2 年后仍具有≥800 pfu/ml 的中和抗体滴度。
结论
马的肌肉内 BPV-1 L1 VLP 接种是安全的，可产生针对 BPV-1 的持久抗体反应。中和抗体滴度诱导至与实验动物和人类的保护相关的水平。
潜在相关性
BPV-1 L1 VLP 是预防马等动物 BPV-1/-2 诱导疾病的有前途的疫苗候选物。
Zotero 插件